Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Depostat

Known as: Primostat, Schering Brand of Gestonorone Caproate 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2000
Review
2000
Angiogenesis is known to be a critical process for the tumor growth and metastasis. There are many indigenous role-players in… Expand
1979
1979
  • D. Guthrie
  • British journal of obstetrics and gynaecology
  • 1979
  • Corpus ID: 31408925
Fifty‐four patients with advanced cystadenocarcinoma of the ovary were treated with gestronol (Depostat), 200 mg/week, by… Expand
1978
1978
Depostat treatment was found to reduce plasma testosterone and to have a gonadotrophin suppressive effect in males. In our study… Expand
1976
1976
One of the synthetic progestogenic compounds, Primostat,* has been proposed for the medical treatment of benign prostatic… Expand
1975
1975
Abstract Selective uptake of H3-testosterone in human benign prostatic hypertrophy (BPH) has been demonstrated by in vitro and in… Expand
1975
1975
The results of combined treatment with 90 mg estradiol valerianate and 300 mg 17-alpha-hydroxy-19-norprogesterone-capronate (SH… Expand
1973
1973
A clinical evaluation of nor progesterone caproate (Primostat) suggests that this drug has a limited place in the treatment of… Expand
1973
1973
  • Drug and therapeutics bulletin
  • 1973
  • Corpus ID: 40461129
Benign prostatic hyperplasia is a major problem. Treatment should relieve symptoms and prevent progressive deterioration in upper… Expand
1969
1969
The 4‐hr tissue Zn65 uptake, the prostatic, seminal vesicular, and testicular weight ratios, and the caudal prostatic… Expand